R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

Pharmacology Biochemistry and Behavior

Volumn 116, Issue , 2014, Pages 137-141

  Zhang, Ji Chun ^a   Li, Su Xia ^a,b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b PEKING UNIVERSITY   (China)

Author keywords

Antidepressant; Depression; Ketamine; NMDA receptor; R ketamine; S ketamine

Indexed keywords

DEXAMETHASONE; KETAMINE; SUCROSE; ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FORCED SWIM TEST; IMMOBILITY; ISOMER; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; MOUSE; STEREOISOMERISM;

MUS;

ANIMALS; ANTIDEPRESSIVE AGENTS; KETAMINE; MICE; STEREOISOMERISM;

EID: 84889953872     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.11.033     Document Type: Article

References (32)

1. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
2. E.F. Domino Taming the ketamine tiger. 1965 Anesthesiology 113 2010 678 686
3. R.S. Duman, N. Li, R.J. Liu, V. Duric, and G. Aghajanian Signaling pathways underlying the rapid antidepressant actions of ketamine Neuropharmacology 62 2012 35 41
4. K. Hashimoto Emerging role of glutamate in the pathophysiology of major depressive disorder Brain Res Rev 61 2009 105 123
5. K. Hashimoto The role of glutamate on the action of antidepressants Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1558 1568
6. K. Hashimoto Therapeutic implications for NMDA receptors in mood disorders Expert Rev Neurother 13 2013 735 737
7. K. Hashimoto, A. Sawa, and M. Iyo Increased levels of glutamate in brains from patients with mood disorders Biol Psychiatry 62 2007 1310 1316
8. K. Hashimoto, B. Malchow, P. Falkai, and P. Schmitt Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders Eur Arch Psychiatry Clin Neurosci 263 2013 367 377
9. U. Heresco-Levy, and D.C. Javitt The role of N-methyl-d-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes Eur Neuropsychopharmacol 8 1998 141 152
10. S.A. Irwin, A. Iglewicz, R.A. Nelesen, J.Y. Lo, C.H. Carr, and S.D. Romero Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial J Palliat Med 16 2013 958 965
11. D.C. Javitt Glutamate as a therapeutic target in psychiatric disorders Mol Psychiatry 9 2004 984 997
12. R. Kohrs, and M.E. Durieux Ketamine: teaching an old drug new tricks Anesth Analg 87 1998 1186 1193
13. J.H. Krystal, G. Sanacora, and R.S. Duman Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond Biol Psychiatry 73 2013 1133 1141
14. K.A. Lapidus, L. Soleimani, and J.W. Murrough Novel glutamatergic drugs for the treatment of mood disorders Neuropsychiatr Dis Treat 9 2013 1101 1112
15. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, and M. Iwata mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
16. S.X. Li, Y. Fujita, J.C. Zhang, Q. Ren, T. Ishima, and J. Wu Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure Neurobiol Dis 62 2014 124 134
17. R. Machado-Vieira, G. Salvadore, N. Diazgranados, and C.A. Zarate Jr. Ketamine and the next generation of antidepressants with a rapid onset of action Pharmacol Ther 123 2009 143 150
18. S. Maeng, and C.A. Zarate Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects Curr Psychiatry Rep 9 2007 467 474
19. R. Moaddel, G. Abdrakhmanova, J. Kozak, K. Jozwiak, L. Toll, and L. Jimenez Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors Eur J Pharmacol 698 2013 228 234
20. J.W. Murrough Ketamine as a novel antidepressant: from synapse to behavior Clin Pharmacol Ther 91 2012 303 309
21. J.W. Murrough, D.V. Iosifescu, L.C. Chang, R.K. Al Jurdi, C.E. Green, and A.M. Perez Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am J Psychiatry 170 2013 1134 1142
22. G. Paslakis, M. Gilles, A. Meyer-Lindenberg, and M. Deuschle Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series Pharmacopsychiatry 43 2010 33 35
23. R. Paul, N. Schaaff, F. Padberg, H.J. Möller, and T. Frodl Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report from two cases World J Biol Psychiatry 10 2009 241 244
24. C. Pittenger, G. Sanacora, and J.H. Krystal The NMDA receptor as a therapeutic target in major depressive disorder CNS Neurol Disord Drug Targets 6 2007 101 115
25. M.J. Robson, M. Elliott, M.J. Seminerio, and R.R. Matsumoto Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo Eur Neuropsychopharmacol 22 2012 308 317
26. A.J. Rush Ketamine for treatment-resistant depression: ready or not for clinical use Am J Psychiatry 170 2013 1079 1081
27. Steiner K, Gangkofner S, Grunenwald JM. Racemic separation of ketamine. 1997. Patent number: 6,040,479. (March 21, 2000).
28. F.X. Vollenweider, K.L. Leenders, I. ∅ye, D. Hell, and J. Angst Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET) Eur Neuropsychopharmacol 7 1997 25 38
29. T. Yamakura, L.E. Chavez-Noriega, and R.A. Harris Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine Anesthesiology 92 2000 1144 1153
30. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
31. C.A. Zarate Jr., R. Machado-Vieira, I. Henter, L. Ibrahim, N. Diazgranados, and G. Salvadore Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18 2010 293 303
32. C.A. Zarate Jr., D.C. Mathews, and M.L. Furey Human biomarkers of rapid antidepressant effects Biol Psychiatry 73 2013 1142 1155